Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.40 |
| ▸ | NQO2 | P16083 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969903 | 0.79 | CYP1A2 (0.41) | NNMTCYP1A2KMT2APDE10ANQO2 | |
| SCHEMBL30207735 | 0.79 | CYP1A2 (0.41) | NNMTCYP1A2KMT2APDE10ANQO2 | |
| SCHEMBL2661558 | 0.78 | NNMT (0.34) | NNMT | |
| SCHEMBL29850137 | 0.77 | POLB (0.50) | NNMTCYP1A2KMT2APDE10ANQO2 | |
| SCHEMBL1460108 | 0.77 | POLB (0.50) | NNMTCYP1A2KMT2APDE10ANQO2 | |
| SCHEMBL16783076 | 0.77 | BTK (0.37) | KMT2ATDP1MAPTNPC1ALDH1A1 | |
| SCHEMBL2842368 | 0.77 | ALDH1A1 (0.37) | NNMTCYP1A2KMT2APDE10APOLB | |
| SCHEMBL15228340 | 0.77 | TSHR (0.44) | KMT2ATDP1MAPTNPC1ALDH1A1 | |
| SCHEMBL172558 | 0.76 | NNMT (0.52) | NNMTCYP1A2KMT2APDE10APOLB | |
| SCHEMBL15512652 | 0.76 | HTT (0.37) | NNMTCYP1A2KMT2APDE10ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028443-B | Preparation method of tricyclic compound drug intermediate for regulating FXR activity | 济南周行医药科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12565504-B2 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250325526-A1 | USE OF TETRAHYDRONAPHTHYRIDINE DERIVATIVE FOR PREPARING PRODUCT FOR IMPROVING HYPERPIGMENTATION | SCINNOHUB PHARMACEUTICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-115703776-B | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4534084-A1 | USE OF TETRAHYDRONAPHTHYRIDINE DERIVATIVE FOR PREPARING PRODUCT FOR IMPROVING HYPERPIGMENTATION | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025061141-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES | 成都思倍博医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2005051954-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004087710-A1 | PYRROLO`1,2-B!PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040204414-A1 | Pyrrolo[1,2-B]pyridazine compounds and their uses | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| EP-1368094-A4 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040014760-A1 | 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | GILLIGAN PAUL J (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1368094-A1 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | Bristol-Myers Squibb Pharma Company (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030125330-A1 | 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-03 | — | — | US | disclosed |
| WO-2002072202-A1 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO-[1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-0652875-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565504-B2 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, ST6GAL1, MGAT1 | NNMT 4717/4885CYP1A2 515/4885KMT2A 4647/4885 |
| US-20040204414-A1 | Pyrrolo[1,2-B]pyridazine compounds and their uses | CRHR1, CRHR2, CRH | NNMT 3521/4885CYP1A2 502/4885KMT2A 3065/4885 |
| US-20250325526-A1 | USE OF TETRAHYDRONAPHTHYRIDINE DERIVATIVE FOR PREPARING PRODUCT FOR IMPROVING HYPERPIGMENTATION | MC1R, NISCH, TYR | NNMT 86/4885CYP1A2 199/4885KMT2A 2243/4885 |
| US-20030125330-A1 | 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | CRHR2, CRH, CRHR1 | NNMT 4773/4885CYP1A2 929/4885KMT2A 2688/4885 |
| US-20040014760-A1 | 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | CRHR2, CRH, CRHR1 | NNMT 4773/4885CYP1A2 929/4885KMT2A 2688/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | NNMT 388/4885CYP1A2 2970/4885KMT2A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.